Eli Lilly 2008 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

PORTFOLIO AND PIPELINE
10
Select Drug Candidates in Late-Stage Investigation
Arzoxifene for the prevention and treatment of osteoporosis and invasive breast cancer risk reduction
Cetuximab for lung, gastric, esophageal, and adjuvant colorectal cancers
Dirucotide for secondary progressive multiple sclerosis (SPMS)
(in collaboration with BioMS Medical Corp.)
Duloxetine for chronic pain
Enzastaurin for diffuse large B-cell lymphoma
Exenatide for once weekly dosing
IMC-1121B for breast cancer
Prasugrel for patients with acute coronary syndromes who are being medically managed
Semagacestat for Alzheimer’s disease (gamma secretase inhibitor)
Teplizumab for type 1 diabetes
(in collaboration with Macrogenics Inc.)
Select Drug Candidates in Mid-Stage Investigation
BAFF Antibody for rheumatoid arthritis
Basal Insulin Analog for diabetes
CD20 Antibody for non-Hodgkins lymphoma (NHL)
Eg5 Inhibitor for solid tumors
(in collaboration with Kyowa Hakko Kirin Co., Ltd)
eIF-4E ASO for solid tumors
FGF-21 Variant for type 2 diabetes
Gemcitabine Prodrug for solid tumors
GLP-1 Analog Fc for type 2 diabetes
GLP-1 Analog PEG for type 2 diabetes
Glucokinase Activator for type 2 diabetes
(in collaboration with OSI Pharmaceuticals, Inc.)
iGluR5 Antagonist for pain
IL-1 Antibody for type 2 diabetes
IL-17 Antibody for rheumatoid arthritis
IL-23 Antibody for multiple sclerosis
IMC-A12 for solid tumors